In a bold move to expand its reach in specialty healthcare, Cardinal Health has announced it will acquire significant assets in gastroenterology and diabetes care through two high-stakes deals worth a combined $3.9 billion. The U.S.-based pharmaceutical and healthcare giant is set to take a controlling interest in GI Alliance, the largest independent gastroenterology care […]
Cardinal Health has reached a definitive agreement to acquire Integrated Oncology Network (ION) for $1.12 billion in cash. The acquisition is a major move within the healthcare industry as Cardinal Health expands its reach into the independent oncology sector. ION, with its 50 practice sites across ten U.S. states and over 100 providers, plays a […]
Cardinal Health (NYSE: CAH), a leading healthcare services and products company, today revealed its definitive agreement to acquire Specialty Networks for $1.2 billion in cash. Specialty Networks, known for its technology-enabled multi-specialty group purchasing and practice enhancement organization, brings a wealth of clinical and economic value to independent specialty providers. The acquisition significantly strengthens Cardinal […]
US healthcare company Cardinal Health has agreed to divest its Cordis medical devices business to private equity company Hellman & Friedman (H&F) for about $1 billion. Hellman & Friedman is being partnered by Ajax Health, a venture capital company, and Zeus Health, a KKR-backed medical device platform, in the transaction. Cordis is engaged in the […]
In a significant move within the pharmaceutical sector, Shanghai Pharmaceuticals Holding Co. has agreed to purchase the Chinese pharmaceutical distribution business of US-based Cardinal Health for $557 million. The deal, announced amid looming drug distribution reforms in China, marks a major shift for Cardinal Health as it reevaluates its growth strategy in the region. Details […]